Stock Ratings | JPMorgan raised its price target for Lumentum (LITE) to $1,280; Canaccord raised its price target for Sagimet Biosciences (SGMT) to $56, representing a potential upside of 496.38%.
Sagimet Biosciences SGMT | 0.00 | |
Zura Bio ZURA | 0.00 | |
Innate Pharma SA IPHA | 0.00 | |
QumulusAI, Inc. QMLS | 0.00 | |
Neurogene Inc. NGNE | 0.00 |
The ratings of major US investment banks are used to track the latest valuations and target prices on Wall Street daily, and to explore potential equity investment opportunities.
Risk warning:
Investing in small-cap stocks can be risky. Be prepared for potential challenges related to liquidity, high volatility, limited information, and financial instability. Always diversify your investments.
Today's key assessments and concerns
Canaccord Genuity: Maintaining a "buy" rating on Sagimet Biosciences Sagimet Biosciences(SGMT.US) ) stock, while raising the price target from $49 to $56.
Wedbush: Maintaining its "Outperform Market" rating for Zura Bio ( Zura Bio(ZURA.US) ), while raising its price target from $15 to $22.
BTIG: Maintaining a "buy" rating on Innate Pharma ( Innate Pharma SA(IPHA.US) ), with a price target raised from $8 to $9.
Chardan Capital: Initial rating for QumulusAI ( QumulusAI, Inc.(QMLS.US) ) stock at "Buy", with a target price of $24.5.
Canaccord Genuity: Maintaining a "buy" rating on Neurogene ( Neurogene Inc.(NGNE.US) ), while lowering its price target from $180 to $166.
| The symbol | Classification | Target price | Current price | Percentage of potential increase/decrease | (Classification) Agency |
| Sagimet Biosciences(SGMT.US) | to lift | $56.0 | $9.39 | 496.38% | Canaccord Genuity |
| Zura Bio(ZURA.US) | to lift | $22.0 | $5.78 | 280.62% | Wedbush |
| Innate Pharma SA(IPHA.US) | to lift | $9.0 | $2.47 | 264.37% | BTIG |
| Zura Bio(ZURA.US) | to lift | $20.0 | $5.78 | 246.02% | |
| Legend Biotech(LEGN.US) | to lift | $49.0 | $20.65 | 137.29% | Morgan Stanley |
| QumulusAI, Inc.(QMLS.US) | Initial classification | $24.5 | $6.29 | 289.51% | Chardan Capital |
| Neurogene Inc.(NGNE.US) | cut | $166.0 | $36.98 | 348.89% | Canaccord Genuity |
| Legend Biotech(LEGN.US) | cut | $78.0 | $20.65 | 277.72% | Barclays |
| BioHarvest Sciences, Inc.(BHST.US) | cut | $8.0 | $2.15 | 272.09% | Roth Capital |
| UpStream Bio(UPB.US) | cut | $25.0 | $6.91 | 261.79% | Truist Securities |
comments:
Target price unit and current price: US Dollar;
Current price: As of the latest closing price of US stocks;
Potential percentage increase/potential decrease = (Agency target price - current price) / current price 100% (Current price = Last closing price up to the time of the count)
Lifting
Wolfe Research: Maintaining its "Outperform Market" rating for CAVA Group CAVA Group, Inc.(CAVA.US) ), while raising its price target from $79 to $82.
UBS: Maintaining a "neutral" rating on Salesforce ( Salesforce.com, inc.(CRM.US) ), while raising its price target from $185 to $210.
TD Cowen: Maintaining a "buy" rating on Circle Internet Group ( Circle(CRCL.US) ), while raising the price target from $82 to $87.
Bernstein: Maintaining its "underperform" rating on CoreWeave ( CoreWeave(CRWV.US) ), while raising its price target from $67 to $74.
Cantor Fitzgerald: Maintaining an "overweight" rating on CoreWeave ( CoreWeave(CRWV.US) ), while raising the price target from $167 to $176.
JP Morgan: Maintaining a "neutral" rating on CoreWeave ( CoreWeave(CRWV.US) ), while raising the price target from $110 to $120.
JP Morgan: Maintaining an "overweight" rating on Lumentum Holdings Lumentum Holdings, Inc.(LITE.US) ), while raising its price target from $1,165 to $1,280.
Mizuho: Maintaining its "Outperform Market" rating for Lumentum Lumentum Holdings, Inc.(LITE.US) , while raising its price target from $1,100 to $1,140.
Morgan Stanley: Maintaining a "Market-Similar Weight" rating for Lumentum Lumentum Holdings, Inc.(LITE.US) , while raising its price target from $900 to $1,000.
Wells Fargo: Maintaining an "overweight" rating on ServiceNow ServiceNow, Inc.(NOW.US) ) stock, while raising its price target from $160 to $175.
Wells Fargo: Maintaining an "overweight" rating on Microsoft Microsoft Corporation(MSFT.US) ) stock, while raising its price target from $650 to $700.
Wedbush: Maintaining a "neutral" rating on Super Micro Computer ( Super Micro Computer, Inc.(SMCI.US) ), while raising the price target from $34 to $40.
Mizuho: Maintaining a "neutral" rating on Super Micro Computer ( Super Micro Computer, Inc.(SMCI.US) ), while raising the price target from $34 to $35.
First Coverage
Piper Sandler: Initial rating for LightPath Technologies ( LightPath Technologies, Inc. Class A(LPTH.US) ) at "overweight", with a target price of $15.
Piper Sandler: Initial rating for Mercury Systems ( Mercury Systems, Inc.(MRCY.US) ) at "overweight", with a price target of $126.
Chardan Capital: Initial rating for QumulusAI ( QumulusAI, Inc.(QMLS.US) ) stock at "Buy", with a target price of $24.5.
reduction
Roth Capital: Affirming a "buy" rating on CAVA Group CAVA Group, Inc.(CAVA.US) ), with a price target cut from $106 to $95.
UBS: Maintaining a "neutral" rating on Intel ( Intel Corporation(INTC.US) ) stock, while lowering its price target from $121 to $112.
TD Securities: Maintaining a "buy" rating on Stereotaxis ( STEREOTAXIS INC(STXS.US) ), while lowering the price target from $5 to $3.
Editor's Note: This content was created by Saham's AI-powered SaaS tool and reviewed by our editorial team.
Risk Warning: Investing involves risk. Securities may rise, fall, or become worthless. Investing does not guarantee profits and may result in losses. Past performance is not necessarily indicative of future results. Before making any investment decision, investors should assess their financial situation, investment objectives, experience, risk tolerance, and understand the nature of the investment products and their associated risks. For more details on the nature and risks of each investment product, please read the relevant offering documents carefully. If you have any questions, it is advisable to seek independent professional advice.